Patrick Forde: What is an acceptable rate of crossover?
Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, shared on X/Twitter:
“On crossover – in 2 phase 3 NSCLC trials (LAURA and KN189) where in-study drug was provided to pts with progression on control arm, rates were 81% and 57%.
So my question to colleagues, Timothée Olivier, Bishal Gyawali and Alfredo Addeo: What is an acceptable rate of crossover? 57%, 81% or 100%?”
Bishal Gyawali further added:
“Agree that the crossover wouldn’t be 100% as we will lose some patients for various reasons. What I have been arguing for is “mandatory” crossover and not “allowing crossover”. When you make it mandatory, the onus is on the sponsor to provide it as subsequent line.
Despite making it mandatory, if the crossover rate is still 85%, then that’s the best case scenario in the real world and can’t complain. But simply saying crossover would be “allowed” and having a 50% crossover rate, wouldn’t be right.
More here.”
Source: Patrick Forde/X and Bishal Gyawali/X
Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives.
Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023